The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of neoadjuvant endocrine therapy (NAET) versus neoadjuvant chemotherapy (NAC) in stage II-III invasive lobular carcinoma (ILC).
 
Jason Mouabbi
Employment - MD Anderson Cancer Center
Honoraria - BostonGene
Consulting or Advisory Role - AstraZeneca; GE Healthcare; Gilead Sciences; Novartis
Research Funding - Bristol Myers Squibb Foundation (Inst)
(OPTIONAL) Uncompensated Relationships - Lobular Breast Cancer Alliance
 
Yara Sakr
No Relationships to Disclose
 
Akshara Singareeka Raghavendra
No Relationships to Disclose
 
Taiwo Adesoye
Consulting or Advisory Role - Boehringer labs
 
Henry Kuerer
Consulting or Advisory Role - Merck; Targeted Medical Education, Inc.
Patents, Royalties, Other Intellectual Property - McGraw-Hill Publishing; NEJM Group
 
Azadeh Nasrazadani
No Relationships to Disclose
 
Amy Hassan
No Relationships to Disclose
 
Ajit Bisen
No Relationships to Disclose
 
Giancarlo Moscol
No Relationships to Disclose
 
Vicente Valero
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Beijing Saint Lucia Hospital Management Consulting Company; Stemline Therapeutics
Travel, Accommodations, Expenses - Genentech/Roche
 
Carlos Barcenas
Research Funding - Personalis (Inst); Puma Biotechnology (Inst)
 
Debasish Tripathy
Consulting or Advisory Role - Ambrx; AstraZeneca; BeiGene; Genomic Health; Gilead Sciences; GlaxoSmithKline; Jazz Pharmaceuticals; Menarini; Novartis; OncoPep; Personalis; Pfizer; Roche; Sermonix Pharmaceuticals; Zetagen
Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Lavinia Middleton
No Relationships to Disclose
 
Rachel Layman
Honoraria - Pfizer
Consulting or Advisory Role - BioTheryX; Celcuity; Gilead Sciences; Lilly; Novartis
Research Funding - Accutar Biotech (Inst); Arvinas (Inst); BioTheryX (Inst); Celcuity (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zentalis (Inst)
(OPTIONAL) Uncompensated Relationships - Celcuity; Lilly
 
Paula Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Honoraria - Dava Oncology; Frontiers Media; OncLive/MJH Life Sciences; SABCS; Seagen
Consulting or Advisory Role - Abbvie; Bolt Biotherapeutics; Caris Life Sciences; HERON; Immunonet BioSciences; Juniper Pharmaceuticals; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Pfizer; Puma Biotechnology; Sirtex Medical
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Bolt Biotherapeutics (Inst); Byondis (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Carisma Therapeutics (Inst); Carisma Therapeutics (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); SEAGEN (Inst); SEAGEN (Inst); SEAGEN (Inst)
Patents, Royalties, Other Intellectual Property - United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377; US-20140086905-A1; US-20140134154-A1; US-20150204879-A1; US-20160053010-A1; US-20230167414-A1
(OPTIONAL) Uncompensated Relationships - ALX Oncology; Jazz Pharmaceuticals; Pfizer
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; Becton Dickinson; Calibr; Cybrexa Therapeutics; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Debiopharm Group; EcoR1 Capital; eFFECTOR Therapeutics; Elevation Oncology; Exelixis; GT Aperion; Guardant Health; Harbinger Health; Incyte; Jazz Pharmaceuticals; LegoChem Biosciences; Loxo/Lilly; Menarini Group; Mersana; Molecular Templates; OnCusp Therapeutics; Protai; Ribometrix; Seagen; Tempus; Theratechnologies; Zentalis; Zymeworks
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)